The Laboratory Developed Test (LDT) would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.
Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.
“This strategic partnership continues our path to fully realize the commercial value of our technology,” said Douglass Simpson, President and CEO of Corgenix. “Our company looks forward to this beneficial partnership, which aims to expand the clinical utility of this advanced cardiac disease biomarker.”
“Our partnership with Corgenix fits perfectly with our strategy to develop best-of-breed biomarkers for the most comprehensive risk factor testing for cardiovascular disease and related diseases,” said Tonya Mallory, President and CEO of HDL, Inc.
LDT’s are at the leading edge of the personalized medicine movement, which includes testing that enables targeted pharmacologic treatment for, and prevention of, heart disease, cancer and other diseases.
Corgenix originally licensed the technology in 2002, and has applied this proprietary technology to the FDA-cleared anti-AtherOx® IgG test kit.